Glenmark Pharma receives ANDA approval for Lacosamide tablets

Glenmark Pharma has received final approval by the US Food and Drug Administration (FDA) for its Lacosamide tablets USP, 50 mg, 100 mg, 150 mg and 200 mg, the generic version of Vimpat tablets, 50 mg, 100 mg, 150 mg and 200 mg of UCB. The company plans to launch the product immediately, Glenmark Pharma said in a statement.

According to IQVIA sales data for the 12-month period ending January 2022, the Vimpat tablets, 50 mg, 100 mg, 150 mg and 200 mg market achieved annual sales of approximately $1.7 billion, the statement added.